NASDAQ:PRAX

Praxis Precision Medicines Competitors

$25.30
-5.07 (-16.69 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$24.97
Now: $25.30
$30.66
50-Day Range
$28.12
MA: $36.22
$50.56
52-Week Range
$23.90
Now: $25.30
$60.95
Volume693,418 shs
Average Volume154,533 shs
Market Capitalization$976.05 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Praxis Precision Medicines (NASDAQ:PRAX) Vs. BHVN, HCM, SAGE, ARNA, EBS, and TPTX

Should you be buying PRAX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Praxis Precision Medicines, including Biohaven Pharmaceutical (BHVN), Hutchison China MediTech (HCM), Sage Therapeutics (SAGE), Arena Pharmaceuticals (ARNA), Emergent BioSolutions (EBS), and Turning Point Therapeutics (TPTX).

Praxis Precision Medicines (NASDAQ:PRAX) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Praxis Precision Medicines and Biohaven Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Praxis Precision Medicines00403.00
Biohaven Pharmaceutical021002.83

Praxis Precision Medicines currently has a consensus target price of $60.3333, suggesting a potential upside of 138.47%. Biohaven Pharmaceutical has a consensus target price of $96.4545, suggesting a potential upside of 28.95%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Biohaven Pharmaceutical.

Insider and Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Praxis Precision Medicines and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Praxis Precision MedicinesN/AN/AN/A
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Valuation and Earnings

This table compares Praxis Precision Medicines and Biohaven Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision MedicinesN/AN/AN/AN/AN/A
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.86

Summary

Praxis Precision Medicines beats Biohaven Pharmaceutical on 4 of the 7 factors compared between the two stocks.

Praxis Precision Medicines (NASDAQ:PRAX) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Praxis Precision Medicines and Hutchison China MediTech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Praxis Precision Medicines00403.00
Hutchison China MediTech00203.00

Praxis Precision Medicines currently has a consensus target price of $60.3333, suggesting a potential upside of 138.47%. Hutchison China MediTech has a consensus target price of $40.00, suggesting a potential upside of 37.03%. Given Praxis Precision Medicines' higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Hutchison China MediTech.

Insider and Institutional Ownership

33.5% of Hutchison China MediTech shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Praxis Precision Medicines and Hutchison China MediTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Praxis Precision MedicinesN/AN/AN/A
Hutchison China MediTechN/AN/AN/A

Valuation and Earnings

This table compares Praxis Precision Medicines and Hutchison China MediTech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision MedicinesN/AN/AN/AN/AN/A
Hutchison China MediTech$204.89 million20.74$-106,020,000.00($0.80)-36.49

Praxis Precision Medicines has higher earnings, but lower revenue than Hutchison China MediTech.

Praxis Precision Medicines (NASDAQ:PRAX) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Praxis Precision Medicines and Sage Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Praxis Precision Medicines00403.00
Sage Therapeutics08802.50

Praxis Precision Medicines currently has a consensus target price of $60.3333, suggesting a potential upside of 138.47%. Sage Therapeutics has a consensus target price of $87.0625, suggesting a potential upside of 15.06%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Sage Therapeutics.

Profitability

This table compares Praxis Precision Medicines and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Praxis Precision MedicinesN/AN/AN/A
Sage Therapeutics-7,706.84%-63.81%-56.64%

Valuation and Earnings

This table compares Praxis Precision Medicines and Sage Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision MedicinesN/AN/AN/AN/AN/A
Sage Therapeutics$6.87 million643.05$-680,240,000.00($13.38)-5.66

Praxis Precision Medicines has higher earnings, but lower revenue than Sage Therapeutics.

Summary

Praxis Precision Medicines beats Sage Therapeutics on 5 of the 7 factors compared between the two stocks.

Praxis Precision Medicines (NASDAQ:PRAX) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Praxis Precision Medicines and Arena Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Praxis Precision Medicines00403.00
Arena Pharmaceuticals001503.00

Praxis Precision Medicines currently has a consensus target price of $60.3333, suggesting a potential upside of 138.47%. Arena Pharmaceuticals has a consensus target price of $92.80, suggesting a potential upside of 37.20%. Given Praxis Precision Medicines' higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Arena Pharmaceuticals.

Insider and Institutional Ownership

89.7% of Arena Pharmaceuticals shares are held by institutional investors. 3.1% of Arena Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Praxis Precision Medicines and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Praxis Precision MedicinesN/AN/AN/A
Arena PharmaceuticalsN/A-33.17%-30.41%

Valuation and Earnings

This table compares Praxis Precision Medicines and Arena Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision MedicinesN/AN/AN/AN/AN/A
Arena Pharmaceuticals$806.43 million5.06$397.55 million$7.698.80

Arena Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines.

Summary

Arena Pharmaceuticals beats Praxis Precision Medicines on 4 of the 7 factors compared between the two stocks.

Praxis Precision Medicines (NASDAQ:PRAX) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Praxis Precision Medicines and Emergent BioSolutions, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Praxis Precision Medicines00403.00
Emergent BioSolutions02502.71

Praxis Precision Medicines currently has a consensus target price of $60.3333, suggesting a potential upside of 138.47%. Emergent BioSolutions has a consensus target price of $113.6667, suggesting a potential upside of 52.63%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Emergent BioSolutions.

Insider and Institutional Ownership

80.2% of Emergent BioSolutions shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Praxis Precision Medicines and Emergent BioSolutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Praxis Precision MedicinesN/AN/AN/A
Emergent BioSolutions12.50%26.68%12.70%

Valuation and Earnings

This table compares Praxis Precision Medicines and Emergent BioSolutions' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision MedicinesN/AN/AN/AN/AN/A
Emergent BioSolutions$1.11 billion3.59$54.50 million$2.9125.59

Emergent BioSolutions has higher revenue and earnings than Praxis Precision Medicines.

Summary

Emergent BioSolutions beats Praxis Precision Medicines on 7 of the 9 factors compared between the two stocks.

Praxis Precision Medicines (NASDAQ:PRAX) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Praxis Precision Medicines and Turning Point Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Praxis Precision Medicines00403.00
Turning Point Therapeutics00703.00

Praxis Precision Medicines currently has a consensus target price of $60.3333, suggesting a potential upside of 138.47%. Turning Point Therapeutics has a consensus target price of $153.7143, suggesting a potential upside of 102.52%. Given Praxis Precision Medicines' higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Turning Point Therapeutics.

Insider and Institutional Ownership

81.3% of Turning Point Therapeutics shares are held by institutional investors. 23.2% of Turning Point Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Praxis Precision Medicines and Turning Point Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Praxis Precision MedicinesN/AN/AN/A
Turning Point TherapeuticsN/A-23.81%-23.08%

Valuation and Earnings

This table compares Praxis Precision Medicines and Turning Point Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision MedicinesN/AN/AN/AN/AN/A
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-25.38

pixel
Ad Oxford Club
Your 15 Minute Workday… (Make Extra Cash from Home)
Some people binge watch Netflix… Hulu…or HBO shows. And some people turn their downtime into cash. James made $2,275 in just 19 minutes…all thanks to something called The 15 Minute Workday. The average trade makes 12% in just 5 days (factoring winners and losers) which is out of this world.

Praxis Precision Medicines Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.80-2.7%$4.52 billionN/A-6.10Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.19-1.5%$4.25 billion$204.89 million-36.49
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$75.67-4.9%$4.20 billion$6.87 million-7.31Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.64-1.8%$4.01 billion$806.43 million-9.58Analyst Report
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$74.47-2.3%$3.88 billion$1.11 billion23.95Analyst Report
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$75.90-1.4%$3.72 billionN/A-21.62Analyst Report
High Trading Volume
News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$53.36-2.4%$3.71 billion$117.91 million-10.82
I-Mab logo
IMAB
I-Mab
1.2$55.09-9.9%$3.57 billion$4.31 million-1.91Increase in Short Interest
LEGN
Legend Biotech
1.2$26.76-1.1%$3.49 billion$64.39 million0.00Decrease in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.14-2.4%$3.41 billion$114.62 million-7.72Analyst Report
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$44.48-5.0%$3.40 billionN/A-5.99News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.90-1.2%$3.33 billion$306.98 million-6.85
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.28-3.2%$3.30 billion$339.08 million-12.37Analyst Report
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.34-0.3%$3.29 billion$36.13 million-70.66Unusual Options Activity
Insmed logo
INSM
Insmed
1.2$33.02-4.1%$3.27 billion$136.47 million-12.70
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$89.75-3.7%$3.13 billion$26.52 million-7.91
Alkermes logo
ALKS
Alkermes
1.2$19.23-1.9%$3.00 billion$1.17 billion-41.80
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$115.44-3.8%$3.00 billionN/A-57.43Insider Selling
News Coverage
Arvinas logo
ARVN
Arvinas
1.5$62.89-2.5%$3.00 billion$42.98 million-24.57News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$69.43-1.7%$2.99 billion$421.03 million24.45Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.69-1.5%$2.94 billion$80.43 million108.05Decrease in Short Interest
Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.80-0.6%$2.77 billion$644.77 million-10.39
OPKO Health logo
OPK
OPKO Health
1.9$4.20-1.7%$2.77 billion$901.90 million-23.33
Organogenesis logo
ORGO
Organogenesis
1.0$21.90-3.7%$2.70 billion$260.98 million-365.00
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.53-3.4%$2.69 billionN/A-23.92
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.98-6.7%$2.64 billion$182.24 million-8.68Analyst Upgrade
Gap Down
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.95-2.9%$2.61 billion$306.49 million25.79
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$32.27-3.8%$2.51 billion$60,000.00-10.02
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.96-5.5%$2.50 billion$25 million-9.19Insider Selling
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$41.47-3.1%$2.50 billion$2.11 million-8.98Analyst Report
News Coverage
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$151.03-2.7%$2.44 billion$120.28 million-152.56Analyst Report
Decrease in Short Interest
News Coverage
Cryoport logo
CYRX
Cryoport
1.9$51.64-1.3%$2.38 billion$33.94 million-89.03
Xencor logo
XNCR
Xencor
1.0$43.17-6.9%$2.33 billion$156.70 million-30.84News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.21-2.3%$2.30 billion$15 million-17.39Unusual Options Activity
ALX Oncology logo
ALXO
ALX Oncology
1.9$59.80-4.5%$2.29 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.81-0.5%$2.20 billion$963.01 million13.61News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$27.83-3.6%$2.05 billion$23.90 million-17.29Analyst Report
Analyst Revision
News Coverage
Amarin logo
AMRN
Amarin
1.6$5.11-0.6%$2.01 billion$429.76 million-102.18News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.55-3.4%$2.00 billionN/A-19.91
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.17-1.3%$1.98 billion$410,000.00-6.12Analyst Report
News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$120.94-4.4%$1.94 billionN/A-10.93
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.65-1.7%$1.92 billion$34.51 million-17.65
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$63.93-2.6%$1.91 billionN/A-27.20Increase in Short Interest
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$47.01-2.9%$1.87 billionN/A0.00Analyst Report
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.80-5.3%$1.87 billion$103.54 million-19.40Insider Selling
MORF
Morphic
1.3$55.98-3.0%$1.87 billion$16.98 million-35.88Insider Selling
Decrease in Short Interest
News Coverage
Kura Oncology logo
KURA
Kura Oncology
1.6$29.20-5.8%$1.82 billionN/A-17.91
FibroGen logo
FGEN
FibroGen
1.8$19.26-2.4%$1.81 billion$256.58 million-7.38Analyst Report
News Coverage
MacroGenics logo
MGNX
MacroGenics
1.2$31.28-5.5%$1.77 billion$64.19 million-9.99Decrease in Short Interest
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.